Techniques in Coloproctology

, Volume 15, Issue 2, pp 129–134

Prophylactic surgery in Lynch syndrome

  • V. Celentano
  • G. Luglio
  • G. Antonelli
  • R. Tarquini
  • L. Bucci
Review

Abstract

Lynch syndrome (LS) is caused by a germline mutations in DNA mismatch repair genes and is a dominantly inherited syndrome, responsible for 2–5% of all colorectal cancer (CRC) cases. Mutation carriers have a 60–85% risk of developing CRC. With the increasing use of genetic predisposition testing, patients and health care providers must decide on cancer risk-reduction strategies. The cancers observed in families with LS are diagnosed at an unusually early age and may be multiple. The decision about which surgery is suitable should be made on the basis of patient factors and preferences, with special emphasis on age, comorbidity, sphincteric function, and the ability of the patient to cope with intensive surveillance. Colectomy decreases the risk of second CRC significantly. The estimated lifetime risk for endometrial adenocarcinoma is 40–60% in women with LS, and the mean age at diagnosis is around 50 years. This risk equals or exceeds the risk of CRC. The optimal management of the elevated risk for cancer in carriers of mutations for hereditary nonpolyposis colorectal cancer is unclear. Patients who are gene mutation carriers should receive counseling about colectomy, and if women, prophylactic hysterectomy and bilateral oophorectomy.

Keywords

Lynch syndrome Hereditary nonpolyposis colorectal cancer Prophylactic surgery 

References

  1. 1.
    Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N Engl J Med 348:919–932PubMedCrossRefGoogle Scholar
  2. 2.
    Aaltonen LA, Salovaara R, Kristo P et al (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481–1487PubMedCrossRefGoogle Scholar
  3. 3.
    Percesepe A, Borghi F, Menigatti M et al (2001) Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 19:3944–3950PubMedGoogle Scholar
  4. 4.
    Rouprêt M, Yates DR, Comperat E, Cussenot O (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 54:1226–1236PubMedCrossRefGoogle Scholar
  5. 5.
    Soravia C, van der Klift H, Bründler MA et al (2003) Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A 121A:159–162PubMedCrossRefGoogle Scholar
  6. 6.
    Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77:1836–1843PubMedCrossRefGoogle Scholar
  7. 7.
    Medina Arana V, Barrios del Pino Y, García-Castro C, González-Aguilera JJ, Fernández-Peralta A, González-Hermoso F (2002) Highly aggressive leiomyosarcoma associated with Lynch II syndrome. Ann Oncol 13:807–808PubMedCrossRefGoogle Scholar
  8. 8.
    Huang RL, Chao CF, Ding DC et al (2004) Multiple epithelial and nonepithelial tumors in hereditary nonpolyposis colorectal cancer:characterization of germline and somatic mutations of the MHS2 gene and heterogeneity of replication error phenotypes. Cancer Genet Cytogenet 153:108–114PubMedCrossRefGoogle Scholar
  9. 9.
    Salovaara R, Loukola A, Kristo P et al (2000) Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 18:2193–2200PubMedGoogle Scholar
  10. 10.
    Molatore S, Ranzani GN (2004) Genetics of colorectal polyps. Tech Coloproctol 2:S240–S242CrossRefGoogle Scholar
  11. 11.
    Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J (1997) Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 57:4749–4756PubMedGoogle Scholar
  12. 12.
    Bronner CE, Baker SM, Morrison PT et al (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colorectal cancer. Nature 368:258–261PubMedCrossRefGoogle Scholar
  13. 13.
    Leach FS, Nicolaides NC, Papadopoulos N et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225PubMedCrossRefGoogle Scholar
  14. 14.
    Nicolaides NC, Papadopoulos N, Liu B et al (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75–80PubMedCrossRefGoogle Scholar
  15. 15.
    Umar A, Boyer JC, Thomas DC et al (1994) Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem 269:14367–14370PubMedGoogle Scholar
  16. 16.
    Menigatti M, Di Gregorio C, Borghi F et al (2001) Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer 31:357–361PubMedCrossRefGoogle Scholar
  17. 17.
    Cunningham JM, Christensen ER, Tester DJ et al (1998) Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455–3460PubMedGoogle Scholar
  18. 18.
    Kastrinos F, Stoffel EM, Balmana J, Steyerberg EW, Mercado R, Syngal S (2008) Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1, 914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev 17:2044–2051PubMedCrossRefGoogle Scholar
  19. 19.
    Kruse R, Rütten A, Lamberti C et al (1998) Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 63:63–70PubMedCrossRefGoogle Scholar
  20. 20.
    Watson P, Vasen HF, Mecklin JP et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449PubMedCrossRefGoogle Scholar
  21. 21.
    Plaschke J, Engel C, Krüger S et al (2004) Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 22:4486–4494PubMedCrossRefGoogle Scholar
  22. 22.
    Senter L, Clendenning M, Sotamaa K et al (2008) The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135:419–428PubMedCrossRefGoogle Scholar
  23. 23.
    Vasen HFA, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424–425PubMedCrossRefGoogle Scholar
  24. 24.
    Vasen HFA, Watson P, Mecklin JP, Lynch HT (1999) ICG-HNPCC. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453–1456PubMedCrossRefGoogle Scholar
  25. 25.
    Umar A, Boland CR, Terdiman JP et al (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRefGoogle Scholar
  26. 26.
    Wahlberg SS, Schmeits J, Thomas G et al (2002) Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 62:3485–3492PubMedGoogle Scholar
  27. 27.
    Aktan-Collan K, Mecklin JP, Järvinen H et al (2000) Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 89:44–50PubMedCrossRefGoogle Scholar
  28. 28.
    Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency:familial colorectal cancer type x JAMA 293:1979–1985Google Scholar
  29. 29.
    Vasen HFA, Wijnen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027PubMedCrossRefGoogle Scholar
  30. 30.
    Love RR (1986) Adenomas are the precursor lesions for malignant growth in nonpolyposis hereditary carcinoma of the colon and rectum. Surg Gynecol Obstet 162:8–12PubMedGoogle Scholar
  31. 31.
    Mecklin JP, Sipponen P, Jarvinen HJ (1986) Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 29:849–853PubMedCrossRefGoogle Scholar
  32. 32.
    Jarvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411PubMedCrossRefGoogle Scholar
  33. 33.
    Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834PubMedCrossRefGoogle Scholar
  34. 34.
    de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum 45:1588–1594CrossRefGoogle Scholar
  35. 35.
    Lindor NM, Petersen GM, Hadley DW et al (2006) Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296:1507–1517PubMedCrossRefGoogle Scholar
  36. 36.
    Dove-Edwin I, Sasieni P, Adams J, Thomas HJ (2005) Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer. BMJ 331:1047PubMedCrossRefGoogle Scholar
  37. 37.
    Mecklin JP, Aarnio M, Läärä E et al (2007) Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. Gastroenterology 133:1093–1098PubMedCrossRefGoogle Scholar
  38. 38.
    Tominaga K, Nakanishi Y, Nimura S, Yokimura K, Sakai Y, Shimoda T (2005) Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma. Dis Colon Rectum 48:92–100PubMedCrossRefGoogle Scholar
  39. 39.
    Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394PubMedCrossRefGoogle Scholar
  40. 40.
    Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD (1985) Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology 89:328–336PubMedGoogle Scholar
  41. 41.
    Winawer S, Fletcher R, Rex D, Gastrointestinal Consortium Panel et al (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124:544–560PubMedCrossRefGoogle Scholar
  42. 42.
    van Rijn JC, Reitsma JB, Stoker J, Bossuyt PM, van Deventer SJ, Dekker E (2006) Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101:343–350PubMedCrossRefGoogle Scholar
  43. 43.
    Waye JD, Kahn O, Auerbach ME (1996) Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 6:343–377PubMedGoogle Scholar
  44. 44.
    Nicholson FB, Barro JL, Atkin W et al (2005) Review article: population screening for colorectal cancer. Aliment Pharmacol Ther 22:1069–1077PubMedCrossRefGoogle Scholar
  45. 45.
    Rabeneck L, Paszat LF, Hilsden RJ et al (2008) Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 135:1899–1906PubMedCrossRefGoogle Scholar
  46. 46.
    Taku K, Sano Y, Fu KI et al (2007) Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan. J Gastroenterol Hepatol 22:1409–1414PubMedCrossRefGoogle Scholar
  47. 47.
    Repici A, Tricerri R (2004) Endoscopic polypectomy: techniques, complications and follow-up. Tech Coloproctol 8:S283–S290PubMedCrossRefGoogle Scholar
  48. 48.
    Levin TR, Zhao W, Conell C et al (2006) Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 145:880–886PubMedGoogle Scholar
  49. 49.
    Hadley DW, Jenkins JF, Dimond E, de Carvalho M, Kirsch I, Palmer CG (2004) Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 22:39–44PubMedCrossRefGoogle Scholar
  50. 50.
    Bleiker EM, Menko FH, Taal BG et al (2005) Screening behavior of individuals at high risk for colorectal cancer. Gastroenterology 128:280–287PubMedCrossRefGoogle Scholar
  51. 51.
    Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM (1998) Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med 129:787–796PubMedGoogle Scholar
  52. 52.
    de Vos tot Nederveen Cappel WH, Buskens E, van Duijvendijk P et al (2003) Decision analysis in the surgical treatment of colorectal cancer due to a mismatch repair gene defect. Gut 52:1752–1755CrossRefGoogle Scholar
  53. 53.
    Natarajan N, Watson P, Silva-Lopez E, Lynch HT (2010) Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 53:77–82PubMedCrossRefGoogle Scholar
  54. 54.
    Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J et al (1997) International Collaborative Group on HNPCC. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg 225:202–207PubMedCrossRefGoogle Scholar
  55. 55.
    Meyer LA, Broaddus RR, Lu KH (2009) Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 16:14–22PubMedGoogle Scholar
  56. 56.
    Aarnio M, Sankila R, Pukkala E et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81:214–218PubMedCrossRefGoogle Scholar
  57. 57.
    Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430–433PubMedCrossRefGoogle Scholar
  58. 58.
    Offit K, Kauff ND (2006) Reducing the risk of gynecologic cancer in the Lynch syndrome. N Engl J Med 354:293–295PubMedCrossRefGoogle Scholar
  59. 59.
    Dunlop MG, Farrington SM, Carothers AD et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110PubMedCrossRefGoogle Scholar
  60. 60.
    Schmeler KM, Lynch HT, Chen LM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354:261–269PubMedCrossRefGoogle Scholar
  61. 61.
    Vasen HF, Stormorken A, Menko FH et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19:4074–4080PubMedGoogle Scholar
  62. 62.
    Watson P, Bützow R, Lynch HT et al (2001) The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82:223–228PubMedCrossRefGoogle Scholar
  63. 63.
    Lynch HT, Casey MJ (2007) Prophylactic surgery prevents endometrial and ovarian cancer in Lynch syndrome. Nat Clin Pract Oncol 4:672–673PubMedCrossRefGoogle Scholar
  64. 64.
    Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovita P, Mecklin JP, Järvinen HJ (2007) Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 120:821–824PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • V. Celentano
    • 1
  • G. Luglio
    • 1
  • G. Antonelli
    • 1
  • R. Tarquini
    • 1
  • L. Bucci
    • 1
  1. 1.Department of General, Oncologic and Video-Assisted SurgeryUniversity “Federico II”NaplesItaly

Personalised recommendations